We have conducted an H2O-15 PET study that involves imaging a
single group of subjects undergoing different treatments in
separate scanning sessions (treatments were not repeated; they
were administered a single time in either one of the sessions).
We would like to examine the shared effects of two of these
treatments (administered in separate sessions) vs. a common
baseline (obtained during one of the sessions). How should we
take this common baseline into account in SPM2?
Thank You,
Trent Bradberry
Contractor
National Institute on Deafness and Other Communication Disorders
National Institutes of Health
Bethesda, MD 20892
|